Skip to main content

Advertisement

SpringerLink
Log in

Prognostic factors in renal cell carcinoma

  • Topic Paper
  • Published:
World Journal of Urology Aims and scope Submit manuscript

Abstract

Purpose

Renal cell carcinoma (RCC) is a very heterogeneous disease with widely varying prognosis. An accurate knowledge of the individual risk of disease progression and mortality after treatment is essential to counsel patients, plan individualized surveillance protocols and select patients for adapted treatment schedules and new clinical trials.

Methods

A systematic review of the literature on prognostic factors of localized and metastatic RCC was performed.

Results

Prognostic factors in RCC include anatomical (TNM classification, tumor size), histological (Fuhrman grade, histologic subtype), clinical (symptoms and performance status), and molecular features. All these features are not perfectly accurate when used alone. Therefore an increasing number of prognostic models or nomograms that include several combined prognostic features have been designed in order to improve predictive accuracy. UCLA Integrated Staging System (UISS) and the Mayo Clinic’s SSIGN score are the two most used prognostic models for localized RCC. In the setting of metastatic RCC the classical anatomical and histological tumor features have little predictive value. However, accurate prognostic models have been designed to predict response to therapy, and progression-free and overall survival. The two most used tools to predict response to immunotherapy are the model designed by the French Group of Immunotherapy and the Motzer’s model. The advent of tyrosine kinase inhibitors and antiangiogenic drugs have deeply changed the treatment of metastatic RCC. Predictive tools that are adapted to the modern targeted therapies are now needed.

Conclusion

There is increasing knowledge on prognostic factors of localized and metastatic RCC. Several predictive models have been developed by combining different prognostic features and are valuable tools for patient counseling, treatment decision-making and trial design. Further research is needed to assess whether the combination of classical prognostic factors with molecular features and information from gene and protein expression profiling can increase the predictive accuracy of the current prognostic models.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Delahunt B, Kittelson JM, McCredie MR, Reeve AE, Stewart JH, Bilous AM (2002) Prognostic importance of tumor size for localized conventional (clear cell) renal cell carcinoma: assessment of TNM T1 and T2 tumor categories and comparison with other prognostic parameters. Cancer 94:658–664

    Article  PubMed  Google Scholar 

  2. Lau WK, Cheville JC, Blute ML, Weaver AL, Zincke H (2002) Prognostic features of pathologic stage T1 renal cell carcinoma after radical nephrectomy. Urology 59:532–537

    Article  PubMed  Google Scholar 

  3. Minervini R, Minervini A, Fontana N, Traversi C, Cristofani R (2000) Evaluation of the 1997 tumour, nodes and metastases classification of renal cell carcinoma: experience in 172 patients. BJU Int 86:199–202

    Article  CAS  PubMed  Google Scholar 

  4. Moch H, Gasser T, Amin MB, Torhorst J, Sauter G, Mihatsch MJ (2000) Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma: a Swiss experience with 588 tumors. Cancer 89:604–614

    Article  CAS  PubMed  Google Scholar 

  5. Zisman A, Pantuck AJ, Dorey F, Chao DH, Gitlitz BJ, Moldawer N, Lazarovici D, de Kernion JB, Figlin RA, Belldegrun AS (2002) Mathematical model to predict individual survival for patients with renal cell carcinoma. J Clin Oncol 20:1368–1374

    Article  PubMed  Google Scholar 

  6. Ficarra V, Schips L, Guille F, Li G, De La Taille A, Prayer Galetti T, Cindolo L, Novara G, Zigeuner RE, Bratti E et al (2005) Multiinstitutional European validation of the 2002 TNM staging system in conventional and papillary localized renal cell carcinoma. Cancer 104:968–974

    Article  PubMed  Google Scholar 

  7. Masuda H, Kurita Y, Fukuta K, Mugiya S, Suzuki K, Fujita K (1998) Significant prognostic factors for 5-year survival after curative resection of renal cell carcinoma. Int J Urol 5:418–422

    Article  CAS  PubMed  Google Scholar 

  8. Sene AP, Hunt L, McMahon RF, Carroll RN (1992) Renal carcinoma in patients undergoing nephrectomy: analysis of survival and prognostic factors. Br J Urol 70:125–134

    Article  CAS  PubMed  Google Scholar 

  9. Golimbu M, Joshi P, Sperber A, Tessler A, Al-Askari S, Morales P (1986) Renal cell carcinoma: survival and prognostic factors. Urology 27:291–301

    Article  CAS  PubMed  Google Scholar 

  10. Thompson RH, Leibovich BC, Cheville JC, Webster WS, Lohse CM, Kwon ED, Frank I, Zincke H, Blute ML (2005) Is renal sinus fat invasion the same as perinephric fat invasion for pT3a renal cell carcinoma? J Urol 174:1218–1221

    Article  PubMed  Google Scholar 

  11. Han KR, Bui MH, Pantuck AJ, Freitas DG, Leibovich BC, Dorey FJ, Zisman A, Janzen NK, Mukouyama H, Figlin RA et al (2003) TNM T3a renal cell carcinoma: adrenal gland involvement is not the same as renal fat invasion. J Urol 169:899–903 discussion 903–894

    Article  PubMed  Google Scholar 

  12. Terrone C, Gontero P, Volpe A, Porpiglia F, Bollito E, Zattoni F, Frea B, Tizzani A, Fontana D, Scarpa RM et al (2008) Proposal of an improved prognostic classification for pT3 renal cell carcinoma. J Urol 180:72–78

    Article  CAS  PubMed  Google Scholar 

  13. Thompson RH, Cheville JC, Lohse CM, Webster WS, Zincke H, Kwon ED, Frank I, Blute ML, Leibovich BC (2005) Reclassification of patients with pT3 and pT4 renal cell carcinoma improves prognostic accuracy. Cancer 104:53–60

    Article  PubMed  Google Scholar 

  14. Ficarra V, Righetti R, D’Amico A, Rubilotta E, Novella G, Malossini G, Mobilio G (2001) Renal vein and vena cava involvement does not affect prognosis in patients with renal cell carcinoma. Oncology 61:10–15

    Article  CAS  PubMed  Google Scholar 

  15. Inoue T, Hashimura T, Iwamura H, Takahashi T, Segawa T, Kakehi Y, Nakano T, Hiura M, Kanematsu A, Katsura Y et al (2000) Multivariate analysis of prognostic determinants after surgery for renal cell carcinoma at Himeji National Hospital. Hinyokika Kiyo 46:229–234

    CAS  PubMed  Google Scholar 

  16. Terrone C, Cracco C, Porpiglia F, Bollito E, Scoffone C, Poggio M, Berruti A, Ragni F, Cossu M, Scarpa RM et al (2006) Reassessing the current TNM lymph node staging for renal cell carcinoma. Eur Urol 49:324–331

    Article  PubMed  Google Scholar 

  17. Fuhrman SA, Lasky LC, Limas C (1982) Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 6:655–663

    CAS  PubMed  Google Scholar 

  18. Medeiros LJ, Gelb AB, Weiss LM (1988) Renal cell carcinoma. Prognostic significance of morphologic parameters in 121 cases. Cancer 61:1639–1651

    Article  CAS  PubMed  Google Scholar 

  19. Ficarra V, Righetti R, Martignoni G, D’Amico A, Pilloni S, Rubilotta E, Malossini G, Mobilio G (2001) Prognostic value of renal cell carcinoma nuclear grading: multivariate analysis of 333 cases. Urol Int 67:130–134

    Article  CAS  PubMed  Google Scholar 

  20. Rioux-Leclercq N, Karakiewicz PI, Trinh QD, Ficarra V, Cindolo L, De la Taille A, Tostain J, Zigeuner R, Mejean A, Patard JJ (2007) Prognostic ability of simplified nuclear grading of renal cell carcinoma. Cancer 109:868–874

    Article  PubMed  Google Scholar 

  21. Delahunt B, Sika-Paotonu D, Bethwaite PB, McCredie MR, Martignoni G, Eble JN, Jordan TW (2007) Fuhrman grading is not appropriate for chromophobe renal cell carcinoma. Am J Surg Pathol 31:957–960

    Article  PubMed  Google Scholar 

  22. Eble JN, Sauter G, Epstein JI, Sesterhenn IA (2004) Pathology and genetics of tumors of the urinary system and male genital organs. WHO classification of tumors. IARC Press, Lyon

    Google Scholar 

  23. Gudbjartsson T, Hardarson S, Petursdottir V, Thoroddsen A, Magnusson J, Einarsson GV (2005) Histological subtyping and nuclear grading of renal cell carcinoma and their implications for survival: a retrospective nation-wide study of 629 patients. Eur Urol 48:593–600

    Article  PubMed  Google Scholar 

  24. Cheville JC, Lohse CM, Zincke H, Weaver AL, Blute ML (2003) Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol 27:612–624

    Article  PubMed  Google Scholar 

  25. Patard JJ, Leray E, Rioux-Leclercq N, Cindolo L, Ficarra V, Zisman A, De La Taille A, Tostain J, Artibani W, Abbou CC et al (2005) Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol 23:2763–2771

    Article  PubMed  Google Scholar 

  26. Delahunt B, Eble JN, McCredie MR, Bethwaite PB, Stewart JH, Bilous AM (2001) Morphologic typing of papillary renal cell carcinoma: comparison of growth kinetics and patient survival in 66 cases. Hum Pathol 32:590–595

    Article  CAS  PubMed  Google Scholar 

  27. Cheville JC, Lohse CM, Zincke H, Weaver AL, Leibovich BC, Frank I, Blute ML (2004) Sarcomatoid renal cell carcinoma: an examination of underlying histologic subtype and an analysis of associations with patient outcome. Am J Surg Pathol 28:435–441

    Article  PubMed  Google Scholar 

  28. Lee SE, Byun SS, Oh JK, Lee SC, Chang IH, Choe G, Hong SK (2006) Significance of macroscopic tumor necrosis as a prognostic indicator for renal cell carcinoma. J Urol 176:1332–1337 discussion 1337–1338

    Article  PubMed  Google Scholar 

  29. Sengupta S, Lohse CM, Leibovich BC, Frank I, Thompson RH, Webster WS, Zincke H, Blute ML, Cheville JC, Kwon ED (2005) Histologic coagulative tumor necrosis as a prognostic indicator of renal cell carcinoma aggressiveness. Cancer 104:511–520

    Article  PubMed  Google Scholar 

  30. Lam JS, Shvarts O, Said JW, Pantuck AJ, Seligson DB, Aldridge ME, Bui MH, Liu X, Horvath S, Figlin RA et al (2005) Clinicopathologic and molecular correlations of necrosis in the primary tumor of patients with renal cell carcinoma. Cancer 103:2517–2525

    Article  CAS  PubMed  Google Scholar 

  31. Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H (2002) An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol 168:2395–2400

    Article  PubMed  Google Scholar 

  32. Palapattu GS, Pantuck AJ, Dorey F, Said JW, Figlin RA, Belldegrun AS (2003) Collecting system invasion in renal cell carcinoma: impact on prognosis and future staging strategies. J Urol 170:768–772 discussion 772

    Article  PubMed  Google Scholar 

  33. Terrone C, Cracco C, Guercio S, Bollito E, Poggio M, Scoffone C, Tarabuzzi R, Porpiglia F, Scarpa RM, Fontana D et al (2004) Prognostic value of the involvement of the urinary collecting system in renal cell carcinoma. Eur Urol 46:472–476

    Article  CAS  PubMed  Google Scholar 

  34. Uzzo RG, Cherullo EE, Myles J, Novick AC (2002) Renal cell carcinoma invading the urinary collecting system: implications for staging. J Urol 167:2392–2396

    Article  PubMed  Google Scholar 

  35. Kim HL, Belldegrun AS, Freitas DG, Bui MH, Han KR, Dorey FJ, Figlin RA (2003) Paraneoplastic signs and symptoms of renal cell carcinoma: implications for prognosis. J Urol 170:1742–1746

    Article  PubMed  Google Scholar 

  36. Patard JJ, Leray E, Cindolo L, Ficarra V, Rodriguez A, De La Taille A, Tostain J, Artibani W, Abbou CC, Guille F et al (2004) Multi-institutional validation of a symptom based classification for renal cell carcinoma. J Urol 172:858–862

    Article  PubMed  Google Scholar 

  37. Tsui KH, Shvarts O, Smith RB, Figlin RA, de Kernion JB, Belldegrun A (2000) Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria. J Urol 163:1090–1095 quiz 1295

    Article  CAS  PubMed  Google Scholar 

  38. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J (1999) Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17:2530–2540

    CAS  PubMed  Google Scholar 

  39. Lee CT, Katz J, Fearn PA, Russo P (2002) Mode of presentation of renal cell carcinoma provides prognostic information. Urol Oncol 7:135–140

    Article  PubMed  Google Scholar 

  40. Tsui KH, Shvarts O, Smith RB, Figlin R, de Kernion JB, Belldegrun A (2000) Renal cell carcinoma: prognostic significance of incidentally detected tumors. J Urol 163:426–430

    Article  CAS  PubMed  Google Scholar 

  41. Lam JS, Shvarts O, Leppert JT, Figlin RA, Belldegrun AS (2005) Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy. J Urol 173:1853–1862

    Article  PubMed  Google Scholar 

  42. Patard JJ, Rioux-Leclercq N, Fergelot P (2006) Understanding the importance of smart drugs in renal cell carcinoma. Eur Urol 49:633–643

    Article  CAS  PubMed  Google Scholar 

  43. Eichelberg C, Junker K, Ljungberg B, Moch H (2009) Diagnostic and prognostic molecular markers for renal cell carcinoma: a critical appraisal of the current state of research and clinical applicability. Eur Urol 55:851–863

    Article  CAS  PubMed  Google Scholar 

  44. Di Napoli A, Signoretti S (2009) Tissue biomarkers in renal cell carcinoma: issues and solutions. Cancer 115:2290–2297

    Article  PubMed  Google Scholar 

  45. Yao M, Yoshida M, Kishida T, Nakaigawa N, Baba M, Kobayashi K, Miura T, Moriyama M, Nagashima Y, Nakatani Y et al (2002) VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma. J Natl Cancer Inst 94:1569–1575

    CAS  PubMed  Google Scholar 

  46. Schraml P, Struckmann K, Hatz F, Sonnet S, Kully C, Gasser T, Sauter G, Mihatsch MJ, Moch H (2002) VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma. J Pathol 196:186–193

    Article  CAS  PubMed  Google Scholar 

  47. Na X, Wu G, Ryan CK, Schoen SR, di’Santagnese PA, Messing EM (2003) Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas. J Urol 170:588–592

    Article  CAS  PubMed  Google Scholar 

  48. Jacobsen J, Grankvist K, Rasmuson T, Bergh A, Landberg G, Ljungberg B (2004) Expression of vascular endothelial growth factor protein in human renal cell carcinoma. BJU Int 93:297–302

    Article  CAS  PubMed  Google Scholar 

  49. Bui MH, Seligson D, Han KR, Pantuck AJ, Dorey FJ, Huang Y, Horvath S, Leibovich BC, Chopra S, Liao SY et al (2003) Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res 9:802–811

    CAS  PubMed  Google Scholar 

  50. Bui MH, Visapaa H, Seligson D, Kim H, Han KR, Huang Y, Horvath S, Stanbridge EJ, Palotie A, Figlin RA et al (2004) Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma. J Urol 171:2461–2466

    Article  PubMed  Google Scholar 

  51. Leibovich BC, Sheinin Y, Lohse CM, Thompson RH, Cheville JC, Zavada J, Kwon ED (2007) Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma. J Clin Oncol 25:4757–4764

    Article  PubMed  Google Scholar 

  52. Shvarts O, Seligson D, Lam J, Shi T, Horvath S, Figlin R, Belldegrun A, Pantuck AJ (2005) p53 is an independent predictor of tumor recurrence and progression after nephrectomy in patients with localized renal cell carcinoma. J Urol 173:725–728

    Article  CAS  PubMed  Google Scholar 

  53. Kallakury BV, Karikehalli S, Haholu A, Sheehan CE, Azumi N, Ross JS (2001) Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma. Clin Cancer Res 7:3113–3119

    CAS  PubMed  Google Scholar 

  54. Kugler A, Hemmerlein B, Thelen P, Kallerhoff M, Radzun HJ, Ringert RH (1998) Expression of metalloproteinase 2 and 9 and their inhibitors in renal cell carcinoma. J Urol 160:1914–1918

    Article  CAS  PubMed  Google Scholar 

  55. Gilbert SM, Whitson JM, Mansukhani M, Buttyan R, Benson MC, Olsson CA, Sawczuk IS, McKiernan JM (2006) Detection of carbonic anhydrase-9 gene expression in peripheral blood cells predicts risk of disease recurrence in patients with renal cortical tumors. Urology 67:942–945

    Article  PubMed  Google Scholar 

  56. Klatte T, Bohm M, Nelius T, Filleur S, Reiher F, Allhoff EP (2007) Evaluation of peri-operative peripheral and renal venous levels of pro- and anti-angiogenic factors and their relevance in patients with renal cell carcinoma. BJU Int 100:209–214

    Article  CAS  PubMed  Google Scholar 

  57. Rasmuson T, Grankvist K, Jacobsen J, Olsson T, Ljungberg B (2004) Serum insulin-like growth factor-1 is an independent predictor of prognosis in patients with renal cell carcinoma. Acta Oncol 43:744–748

    Article  CAS  PubMed  Google Scholar 

  58. Kim HL, Seligson D, Liu X, Janzen N, Bui MH, Yu H, Shi T, Figlin RA, Horvath S, Belldegrun AS (2004) Using protein expressions to predict survival in clear cell renal carcinoma. Clin Cancer Res 10:5464–5471

    Article  CAS  PubMed  Google Scholar 

  59. Kattan MW, Reuter V, Motzer RJ, Katz J, Russo P (2001) A postoperative prognostic nomogram for renal cell carcinoma. J Urol 166:63–67

    Article  CAS  PubMed  Google Scholar 

  60. Cindolo L, Patard JJ, Chiodini P, Schips L, Ficarra V, Tostain J, De La Taille A, Altieri V, Lobel B, Zigeuner RE et al (2005) Comparison of predictive accuracy of four prognostic models for nonmetastatic renal cell carcinoma after nephrectomy: a multicenter European study. Cancer 104:1362–1371

    Article  PubMed  Google Scholar 

  61. Hupertan V, Roupret M, Poisson JF, Chretien Y, Dufour B, Thiounn N, Mejean A (2006) Low predictive accuracy of the Kattan postoperative nomogram for renal cell carcinoma recurrence in a population of French patients. Cancer 107:2604–2608

    Article  PubMed  Google Scholar 

  62. Isbarn H, Karakiewicz PI (2009) Predicting cancer-control outcomes in patients with renal cell carcinoma. Curr Opin Urol 19:247–257

    Article  PubMed  Google Scholar 

  63. Sorbellini M, Kattan MW, Snyder ME, Reuter V, Motzer R, Goetzl M, McKiernan J, Russo P (2005) A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma. J Urol 173:48–51

    Article  PubMed  Google Scholar 

  64. Zisman A, Pantuck AJ, Wieder J, Chao DH, Dorey F, Said JW, de Kernion JB, Figlin RA, Belldegrun AS (2002) Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol 20:4559–4566

    Article  PubMed  Google Scholar 

  65. Zisman A, Pantuck AJ, Dorey F, Said JW, Shvarts O, Quintana D, Gitlitz BJ, de Kernion JB, Figlin RA, Belldegrun AS (2001) Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol 19:1649–1657

    CAS  PubMed  Google Scholar 

  66. Patard JJ, Kim HL, Lam JS, Dorey FJ, Pantuck AJ, Zisman A, Ficarra V, Han KR, Cindolo L, De La Taille A et al (2004) Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study. J Clin Oncol 22:3316–3322

    Article  PubMed  Google Scholar 

  67. Fujii Y, Saito K, Iimura Y, Sakai Y, Koga F, Kawakami S, Kumagai J, Kihara K (2008) External validation of the Mayo Clinic cancer specific survival score in a Japanese series of clear cell renal cell carcinoma. J Urol 180:1290–1295 discussion 1295-1296

    Article  PubMed  Google Scholar 

  68. Ficarra V, Martignoni G, Lohse C, Novara G, Pea M, Cavalleri S, Artibani W (2006) External validation of the Mayo clinic stage, size, grade and necrosis (SSIGN) score to predict cancer specific survival using a European series of conventional renal cell carcinoma. J Urol 175:1235–1239

    Article  PubMed  Google Scholar 

  69. Zigeuner R, Hutterer G, Chromecki T, Imamovic A, Kampel-Kettner K, Rehak P, Langner C, Pummer K (2008) External validation of the Mayo clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathology. Eur Urol 57:102–109

    Article  PubMed  Google Scholar 

  70. Karakiewicz PI, Briganti A, Chun FK, Trinh QD, Perrotte P, Ficarra V, Cindolo L, De la Taille A, Tostain J, Mulders PF et al (2007) Multi-institutional validation of a new renal cancer-specific survival nomogram. J Clin Oncol 25:1316–1322

    Article  PubMed  Google Scholar 

  71. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125–134

    Article  CAS  PubMed  Google Scholar 

  72. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115–124

    Article  CAS  PubMed  Google Scholar 

  73. Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R (2001) Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 358:966–970

    Article  CAS  PubMed  Google Scholar 

  74. Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, Caton JR Jr, Munshi N, Crawford ED (2001) Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 345:1655–1659

    Article  CAS  PubMed  Google Scholar 

  75. Margulis V, Matin SF, Wood CG (2008) Cytoreductive nephrectomy in metastatic renal cell carcinoma. Curr Opin Urol 18:474–480

    Article  PubMed  Google Scholar 

  76. Eggener SE, Yossepowitch O, Kundu S, Motzer RJ, Russo P (2008) Risk score and metastasectomy independently impact prognosis of patients with recurrent renal cell carcinoma. J Urol 180:873–878 discussion 878

    Article  PubMed  Google Scholar 

  77. Kavolius JP, Mastorakos DP, Pavlovich C, Russo P, Burt ME, Brady MS (1998) Resection of metastatic renal cell carcinoma. J Clin Oncol 16:2261–2266

    CAS  PubMed  Google Scholar 

  78. Pfannschmidt J, Hoffmann H, Muley T, Krysa S, Trainer C, Dienemann H (2002) Prognostic factors for survival after pulmonary resection of metastatic renal cell carcinoma. Ann Thorac Surg 74:1653–1657

    Article  PubMed  Google Scholar 

  79. Kuruvath S, Naidu S, Bhattacharyya M, Benjamin JC, O’Donovan DG (2007) Spinal metastasis from renal cell carcinoma, 31 years following nephrectomy-case report. Clin Neuropathol 26:176–179

    CAS  PubMed  Google Scholar 

  80. Shuch B, La Rochelle JC, Klatte T, Riggs SB, Liu W, Kabbinavar FF, Pantuck AJ, Belldegrun AS (2008) Brain metastasis from renal cell carcinoma: presentation, recurrence, and survival. Cancer 113:1641–1648

    Article  PubMed  Google Scholar 

  81. Upton MP, Parker RA, Youmans A, McDermott DF, Atkins MB (2005) Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy. J Immunother 28:488–495

    Article  CAS  PubMed  Google Scholar 

  82. Mian BM, Bhadkamkar N, Slaton JW, Pisters PW, Daliani D, Swanson DA, Pisters LL (2002) Prognostic factors and survival of patients with sarcomatoid renal cell carcinoma. J Urol 167:65–70

    Article  PubMed  Google Scholar 

  83. de Reijke TM, Bellmunt J, van Poppel H, Marreaud S, Aapro M (2009) EORTC-GU group expert opinion on metastatic renal cell cancer. Eur J Cancer 45:765–773

    Article  PubMed  Google Scholar 

  84. Choueiri TK, Garcia JA, Elson P, Khasawneh M, Usman S, Golshayan AR, Baz RC, Wood L, Rini BI, Bukowski RM (2007) Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer 110:543–550

    Article  CAS  PubMed  Google Scholar 

  85. Motzer RJ, Bukowski RM, Figlin RA, Hutson TE, Michaelson MD, Kim ST, Baum CM, Kattan MW (2008) Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma. Cancer 113:1552–1558

    Article  CAS  PubMed  Google Scholar 

  86. Negrier S, Gomez F, Douillard JY, Ravaud A, Chevreau C, Buclon M, Perol D, Lasset C, Escudier B (2005) Prognostic factors of response or failure of treatment in patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Francais d’Immunotherapie. World J Urol 23:161–165

    Article  CAS  PubMed  Google Scholar 

  87. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M (2002) Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20:289–296

    Article  CAS  PubMed  Google Scholar 

  88. Alamdari FI, Rasmuson T, Grankvist K, Ljungberg B (2007) Angiogenesis and other markers for prediction of survival in metastatic renal cell carcinoma. Scand J Urol Nephrol 41:5–9

    Article  CAS  PubMed  Google Scholar 

  89. Deprimo SE, Bello CL, Smeraglia J, Baum CM, Spinella D, Rini BI, Michaelson MD, Motzer RJ (2007) Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J Transl Med 5:32

    Article  PubMed  CAS  Google Scholar 

  90. Pantuck AJ, Seligson DB, Klatte T, Yu H, Leppert JT, Moore L, O’Toole T, Gibbons J, Belldegrun AS, Figlin RA (2007) Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer 109:2257–2267

    Article  CAS  PubMed  Google Scholar 

  91. Cho D, Signoretti S, Dabora S, Regan M, Seeley A, Mariotti M, Youmans A, Polivy A, Mandato L, McDermott D et al (2007) Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma. Clin Genitourin Cancer 5:379–385

    Article  CAS  PubMed  Google Scholar 

  92. Negrier S, Escudier B, Gomez F, Douillard JY, Ravaud A, Chevreau C, Buclon M, Perol D, Lasset C (2002) Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Francais d’Immunotherapie. Ann Oncol 13:1460–1468

    Article  CAS  PubMed  Google Scholar 

  93. Mekhail TM, Abou-Jawde RM, Boumerhi G, Malhi S, Wood L, Elson P, Bukowski R (2005) Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 23:832–841

    Article  PubMed  Google Scholar 

  94. Motzer RJ, Bacik J, Schwartz LH, Reuter V, Russo P, Marion S, Mazumdar M (2004) Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 22:454–463

    Article  PubMed  Google Scholar 

  95. Ljungberg B, Hanbury DC, Kuczyk MA, Merseburger AS, Mulders PF, Patard JJ, Sinescu IC (2007) Renal cell carcinoma guideline. Eur Urol 51:1502–1510

    Article  PubMed  Google Scholar 

  96. Patil S, Figlin RA, Hutson TE, Michaelson MD, Negrier S, Kim ST, Huang X, Motzer RJ (2009) Prognostic factors for overall survival wityh sunitinib as first-line therapy in patients with metastatic renal cell carcinoma. ASCO proceedings

  97. Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S et al. (2009) Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 27:5794–5799

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest statement

There is no conflict of interest.

Author information

Authors and Affiliations

  1. Division of Urology, Maggiore della Carità Hospital, University of Eastern Piedmont, Corso Mazzini, 18, 28100, Novara, Italy

    Alessandro Volpe

  2. Department of Urology, University of Rennes-1, Rennes, France

    Jean Jacques Patard

Authors
  1. Alessandro Volpe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jean Jacques Patard
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alessandro Volpe.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Volpe, A., Patard, J.J. Prognostic factors in renal cell carcinoma. World J Urol 28, 319–327 (2010). https://doi.org/10.1007/s00345-010-0540-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00345-010-0540-8

Keywords

Search

Navigation